Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Glutamine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Irinotecan, 5FU, Glutamine |
| 2 | PLACEBO_COMPARATOR | Irinotecan, 5FU, Placebo |
| Name | Type | Description |
|---|---|---|
| Glutamine | DRUG | Glutamine 10 g four times daily starting two days before treatment for six days in total |
| Placebo | OTHER | Glutamine placebo |
Inclusion Criteria: * metastatic colorectal cancer to be treated with FOLFIAT chemo Exclusion Criteria: * severely abnormal liver and kidney function
Top 20 of 77 competitors
Glutamine is an investigational small molecule being studied for use in metastatic colorectal cancer. It is being evaluated as prophylaxis for irinotecan induced diarrhea in patients with this condition. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
Glutamine is an amino acid supplement being studied for its potential protective effects in patients receiving chemotherapy. In the context of metastatic colorectal cancer, it is being investigated for its ability to prevent diarrhea caused by irinotecan, a common chemotherapy agent. The specific molecular target has not been identified.
Glutamine is being developed by Avalon GloboCare Corp., a biopharmaceutical company traded on the stock exchange under the ticker symbol ALBT. The company is conducting clinical research to evaluate the drug's potential in oncology, specifically for supportive care in metastatic colorectal cancer patients undergoing chemotherapy.
Glutamine is in Phase 2 clinical development for metastatic colorectal cancer. It has completed one Phase 2 trial, and the drug remains investigational. It has not received FDA approval and is still undergoing clinical evaluation to determine its safety and efficacy for the intended use.
Glutamine has been studied in one completed Phase 2 clinical trial with the identifier NCT00255229. The trial, titled 'Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrhea,' enrolled 130 participants with metastatic colorectal cancer in Canada. The study was randomized, double-blind, and placebo-controlled, and included biomarker selection.
Glutamine is the amino acid commonly known as L-glutamine, which is the naturally occurring form found in the body and in many foods. In the context of this clinical development program, the drug is referred to simply as Glutamine, and it is being investigated for its supportive care role in metastatic colorectal cancer treatment.